Granules India Limited Business Intelligence Report
Granules India Limited Business Intelligence Report
Quality Scores
Latest Quarterly Earnings Summary
Loading latest quarter…
AI Summary
Granules India is a vertically integrated pharmaceutical manufacturer specializing in APIs, PFIs, and Finished Dosages (FD). Historically a bulk drug manufacturer, it has evolved towards higher-margin finished dosages and complex generics. While the company maintains a dominant global market share in molecules like Paracetamol, Ibuprofen, and Metformin, its recent performance shows a transition phase marked by aggressive capex. Revenue growth has slowed to an 11% 5-year CAGR, and PAT growth has stagnated at 2% over the same period. The business model remains robust but is currently facing…
Key Changes in FY2026
Granules has undergone a significant transformation from a bulk API manufacturer to a vertically integrated player with strong capabilities in PFI and Finished Dosages. This evolution is evident in the margin profile, which peaked during the 2021 supply chain crunch and has since stabilized in the 19-22% range. The company has aggressively expanded its US FDA filings, building a robust portfolio of ANDAs and DMFs to compete in the regulated markets. Its 'Green Pharmaceutical' initiative and digital transformation efforts mentioned in recent announcements suggest a move toward cost leadership and process efficiency. The shift towards higher-value FD (Finished Dosages) has been the primary driver of Revenue CAGR (15% over 10 years). The business is now less of a commodity play and more of a…
Management Commentary
Management has successfully steered Granules from a small-scale solvent recycler to a global generic powerhouse. They exhibit deep technical expertise in 'Core Molecules' and have a clear vision for vertical integration. However, the execution in the last three years has been marred by operational headwinds and slower-than-expected growth in new segments. Communication is transparent through regular concalls and detailed investor presentations. Transparency is generally high, though the trend of decreasing promoter holding (from 53% in 2017 to 38% in 2026 projections) warrants careful monitoring.
Financial Highlights
Granules has demonstrated long-term growth with a 15% 10-year sales CAGR, though recent years show significant deceleration. Operating profit margins have been volatile, peaking at 26% in FY21 before normalizing to roughly 19-21%. Interest costs have surged from ₹23 Cr in FY22 to over ₹100 Cr recently, reflecting increased debt for expansion. While sales doubled between 2019 and 2024, the net profit growth has not kept pace due to depreciation and financing costs. Asset turnover is under pressure as massive CWIP is yet to fully contribute to the top line.
Major Opportunities
- Consistent 10-year revenue compounder at 15%
- Global leadership in high-volume molecules like Paracetamol
- Successful transition from API to higher-margin Finished Dosages
Major Risks
- Inventory days significantly increased to over 200 days
- Recent 5-year sales growth is relatively modest at 10.6%
- Heavy reliance on a few core molecules (concentration risk)
About Granules India Limited's Annual Report & Financial Performance
The latest Granules India Limited annual report (FY2026) is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis, audited financial statements, the director's report, the corporate governance and auditor's reports, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This Business Intelligence Hub consolidates the official filings with AI-generated financial analysis so investors can see how revenue, operating margin, cash flow quality, capex, dividends, net debt and management outlook have changed — without reading the entire filing.
What this Granules India Limited research covers
- Fundamental & business analysis
- Financial statements & performance
- Management commentary & discussion
- Corporate governance & auditor report
- Cash flow analysis & capital allocation
- Valuation analysis & business quality
- Growth analysis & competitive position
- Risk, SWOT & moat analysis
- Quarterly earnings & conference-call summary
- Sector, industry & peer comparison
- Latest official company filings
- Business outlook & long-term growth
Granules India Limited — Frequently Asked Questions
Explore more Granules India Limited research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.